Expression of Type 5 Somatostatin Receptor in TSH-secreting Pituitary Adenomas: A Possible Marker for Predicting Long-term Response to Octreotide Therapy

2007 ◽  
Vol 54 (1) ◽  
pp. 133-138 ◽  
Author(s):  
Ai YOSHIHARA ◽  
Osamu ISOZAKI ◽  
Naomi HIZUKA ◽  
Yasuko NOZOE ◽  
Chie HARADA ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Somatostatin Receptor ◽  
Octreotide Therapy ◽  
Term Response

scholarly journals Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review

2021 ◽  
Vol 12 ◽  
Author(s):  
Odelia Cooper ◽  
Vivien Bonert ◽  
Ning-Ai Liu ◽  
Adam N. Mamelak
Keyword(s):  
Radiation Therapy ◽  
Pituitary Adenomas ◽  
Somatostatin Receptor ◽  
Mtor Inhibitors ◽  
Disease Recurrence ◽  
Receptor Ligands ◽  
Somatostatin Receptor Ligands ◽  
Individualized Approach ◽  
Evidence Based Guidelines

Management of aggressive pituitary adenomas is challenging due to a paucity of rigorous evidence supporting available treatment approaches. Recent guidelines emphasize the need to maximize standard therapies as well as the use of temozolomide and radiation therapy to treat disease recurrence. However, often these adenomas continue to progress over time, necessitating the use of additional targeted therapies which also impact quality of life and long-term outcomes. In this review, we present 9 cases of aggressive pituitary adenomas to illustrate the importance of a multidisciplinary, individualized approach. The timing and rationale for surgery, radiation therapy, temozolomide, somatostatin receptor ligands, and EGFR, VEGF, and mTOR inhibitors in each case are discussed within the context of evidence-based guidelines and clarify strategies for implementing an individualized approach in the management of these difficult-to-treat-adenomas.

Octreotide-related exocrine pancreatic insufficiency (EPI) in congenital hyperinsulinism

2020 ◽  
Vol 33 (7) ◽  
pp. 947-950 ◽  
Author(s):  
Purificación Ros-Pérez ◽  
Luz Golmayo ◽  
María L. Cilleruelo ◽  
Carolina Gutiérrez ◽  
Patricia Celaya ◽  
...  
Keyword(s):  
Pancreatic Insufficiency ◽  
Somatostatin Receptor ◽  
Exocrine Pancreatic Insufficiency ◽  
Congenital Hyperinsulinism ◽  
Case Presentation ◽  
Clinical Onset ◽  
Octreotide Therapy ◽  
K Deficiency ◽  
Long Acting

AbstractBackgroundCongenital hyperinsulinism (CH) is the most frequent cause of persistent hypoglycemia in the newborn. Octreotide, a long-acting somatostatin receptor analog (SSRA), is a second line treatment for diazoxide unresponsive CH patients. Although it has been found to be a safe and effective treatment, long-term benefits and side effects, have not been thoroughly evaluated.Case presentationSome authors have indicated that exocrine pancreatic insufficiency (EPI) is a common but under-recognized adverse reaction in adults treated with octreotide. However, no pediatric patient with SSRA-induced EPI has been reported to date. Here we report a case of an infant with diazoxide unresponsive, diffuse CH, caused by a heterozygous pathogenic paternally inherited mutation in the ABCC8 gene (NM_000352.4:c.357del), that developed exocrine pancreatic insufficiency and secondary vitamin K deficiency associated to chronic octreotide therapy.ConclusionsWe point out the atypical clinical onset with a cutaneous hemorrhagic syndrome, emphasizing the clinical relevance of this potential side effect.

scholarly journals gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4857
Author(s):  
Luiz Eduardo Wildemberg ◽  
Daniel Henriques ◽  
Paula C. L. Elias ◽  
Carlos Henrique de A. Lima ◽  
Nina R. de Castro Musolino ◽  
...  
Keyword(s):  
First Generation ◽  
Somatostatin Receptor ◽  
Receptor Ligands ◽  
Biochemical Control ◽  
Molecular Biomarker ◽  
Α Subunit ◽  
Cavernous Sinus Invasion ◽  
Somatostatin Receptor Ligands ◽  
Term Response

Background: It is still controversial if activating mutations in the stimulatory G-protein α subunit (gsp mutation) are a biomarker of response to first generation somatostatin receptor ligands (fg-SRL) treatment in acromegaly. Thus, we aimed to evaluate whether gsp mutation predicts long-term response to fg-SRL treatment and to characterize the phenotype of patients harboring gsp mutations. Methods: GNAS1 sequencing was performed by Sanger. SST2 and SST5 were analyzed by immunohistochemistry (IHC) and real-time RT-PCR. The cytokeratin granulation pattern was evaluated by IHC. Biochemical control was defined as GH < 1.0 ng/mL and normal age-adjusted IGF-I levels. Results: gsp mutation was found in 54 out of 136 patients evaluated. Biochemical control with fg-SRL treatment was similar in gsp+ and gsp- patients (37% vs. 25%, p = 0.219). Tumors harboring gsp mutation were smaller (p = 0.035) and had a lower chance of invading cavernous sinuses (p = 0.001). SST5 protein (p = 0.047) and mRNA (p = 0.013) expression levels were higher in wild-type tumors. Conclusions: In this largest series available in the literature, we concluded that gsp is not a molecular biomarker of response to fg-SRL treatment in acromegaly. However, the importance of its negative association with cavernous sinus invasion and SST5 expression needs to be further investigated.

Somatostatin Receptor Scintigraphy of a Patient with a Giant Invasive Prolactinoma

1999 ◽  
Vol 38 (02) ◽  
pp. 66-67 ◽  
Author(s):  
P. Meyer ◽  
N. I. Bohnen ◽  
A. L. Barkan ◽  
B. Shapiro
Keyword(s):  
Pituitary Adenomas ◽  
Somatostatin Receptor ◽  
Tracer Uptake ◽  
Anterior Skull Base ◽  
Receptor Subtype ◽  
Giant Prolactinoma ◽  
Receptor Scintigraphy ◽  
Octreotide Therapy ◽  
Therapy Prediction ◽  
Invasive Prolactinoma

SummaryA 41-year-old with a giant prolactinoma underwent ln-111 pentetreotide (Octreotide) imaging showing very intense tracer uptake in the region of the anterior skull base. In contrast, there was no significant response to Octreotide therapy. Prediction of clinical responsiveness to Octreotide therapy in patients with pituitary adenomas may depend on the presence of somatostatin receptor subtype 5. Pentetreotide does not avidly bind to this receptor subtype and therefore, cannot be used clinically to predict therapeutic Octreotide responsiveness in patients with large prolactinomas.

Assessment of endocrine disorders of the hypothalamicpituitary axis by nuclear medicine techniques

2002 ◽  
Vol 41 (02) ◽  
pp. 80-90 ◽  
Author(s):  
F. Jockenhövel ◽  
P. Theissen ◽  
M. Dietlein ◽  
W. Krone ◽  
H. Schicha ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Pituitary Adenomas ◽  
Dopamine D2 Receptor ◽  
Somatostatin Receptor ◽  
D2 Receptor ◽  
Ectopic Acth Syndrome ◽  
Endocrine Disorders ◽  
Ectopic Acth ◽  
Number Of Patients ◽  
Hypothalamic Pituitary Axis

SummaryThe following article reviews nuclear medicine techniques which can be used for assessment of endocrine disorders of the hypothalamic-pituitary axis. For planar and SPECT imaging somatostatin-receptor- and dopamine- D2-receptor-scintigraphy are the most widely distributed techniques. These nuclear medicine techniques may be indicated in selected cases to answer differential diagnostic problems. They can be helpful to search for presence and localization of receptor positive tissue. Furthermore they can detect metastasis in the rare cases of a pituitary carcinoma. Scintigraphy with Gallium-67 is suitable for further diagnostic evaluation in suspected hypophysitis. Other SPECT radiopharmaca do not have relevant clinical significance. F-18-FDG as PET radiopharmacon is not ideal because obvious pituitary adenomas could not be visualized. Other PET radiopharmaca including C-11-methionine, C-11-tyrosine, F-18-fluoroethylspiperone, C-11-methylspiperone, and C-11-raclopride are available in specialized centers only. Overall indications for nuclear medicine in studies for the assessment of endocrine disorders of the hypothalamic-pituitary-axis are rare. Original studies often report only about a small number of patients. According to the authors’ opinion the relevance of nuclear medicine in studies of clinically important endocrinologic fields, e. g. localization of small ACTH-producing pituitary adenomas, tumor localization in ectopic ACTH syndrome, localization of recurrent pituitary tissue, assessment of small incidentalomas, can not be definitely given yet.

scholarly journals Adaptation of flocculent anammox culture to low temperature by cold shock: long-term response of microbial population

2021 ◽  
pp. 1-19
Author(s):  
Vojtech Kouba ◽  
Juan Camilo Gerlein ◽  
Andrea Benakova ◽  
Marco Antonio Lopez Marin ◽  
Eva Rysava ◽  
...  
Keyword(s):  
Low Temperature ◽  
Cold Shock ◽  
Microbial Population ◽  
Term Response

Unfolding the case of returnees: How the European Union and its member States are addressing the return of foreign fighters and their families

2021 ◽  
pp. 1-23
Author(s):  
Carlota Rigotti ◽  
Júlia Zomignani Barboza
Keyword(s):  
European Union ◽  
Perceived Threat ◽  
The European Union ◽  
Security Threat ◽  
Short Term ◽  
Member States ◽  
Foreign Fighters ◽  
Term Response

Abstract The return of foreign fighters and their families to the European Union has mostly been considered a security threat by member States, which consequently adopt repressive measures aimed at providing an immediate, short-term response to this perceived threat. In addition to this strong-arm approach, reintegration strategies have also been used to prevent returnees from falling back into terrorism and to break down barriers of hostility between citizens in the long term. Amidst these different strategies, this paper seeks to identify which methods are most desirable for handling returnees.

Sign in / Sign up

Export Citation Format

Share Document